It is still a matter of debate whether nucleoside/nucleotide analogues should be administered as prophylaxis to hepatitis B surface antigen (HBsAg)-negative/antibodies against hepatitis B core antigen (anti-HBc)-positive patients with immunosuppression or whether these patients should be closely monitored and early treatment administered to those who become HBsAg-positive. We describe a reactivation of occult HBV infection emerging with the case of acute hepatitis B in the wife of an HBsAg-negative/anti-HBc-positive subject treated with rituximab-based chemotherapy for chronic lymphocytic leukaemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3851/IMP2826 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Sleeping Giant: Late HBV Reactivation After Rituximab-Based Chemotherapy Despite Correct Prophylaxis.
Int Med Case Rep J
December 2024
Clinical Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
Hepatitis B virus (HBV) reactivation is a recognized complication of long-term immunosuppressive or cytotoxic therapy, typically occurring during immunosuppression or within a few months after treatment. To mitigate this risk, hepatological societies recommend the use of nucleos(t)ide analogues (NA) for HBV reactivation prophylaxis, along with post-treatment monitoring; though, these recommendations are not universally consistent across different guidelines. We present a case of late HBV reactivation in a 76-year-old male with occult HBV infection who received rituximab-based therapy for chronic lymphocytic leukemia.
View Article and Find Full Text PDFThe incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis.
Eur J Gastroenterol Hepatol
January 2025
Gastroenterology Department, Damascus Hospital, Damascus, Syria.
Background: This meta-analysis will evaluate the risk of hepatitis B reactivation in patients treated with ustekinumab for inflammatory bowel disease and psoriasis. We aim to determine the true incidence of this adverse event, reconcile discrepancies in reported reactivation rates, and elucidate the associated risk.
Methods: We conducted a rigorous systematic review adhering to established guidelines.
Multi-omic molecular characterization and diagnostic biomarkers for occult hepatitis B infection and HBsAg-positive hepatitis B infection.
Front Endocrinol (Lausanne)
November 2024
Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, China.
Background: The pathological and physiological characteristics between HBsAg-positive HBV infection and occult hepatitis B infection (OBI) are currently unclear. This study aimed to explore the immune microenvironment in the peripheral circulation of OBI patients through integration of proteomic and metabolomic sequencing, and to identify molecular biomarkers for clinical diagnosis of HBsAg-positive HBV and OBI.
Methods: This research involved collection of plasma from 20 patients with OBI (negative for HBsAg but positive for HBV DNA, with HBV DNA levels < 200 IU/mL), 20 patients with HBsAg-positive HBV infection, and 10 healthy individuals.
Clinical characteristics and long-term treatment outcomes of polypoidal choroidal vasculopathy with classic type leakage.
Sci Rep
September 2024
Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea.
To investigate long-term treatment outcomes of polypoidal choroidal vasculopathy (PCV) with classic type leakage and to compare the outcomes with those of PCV without classic type leakage. This retrospective study included 153 patients diagnosed with PCV and treated with anti-vascular endothelial growth factor (VEGF). Patients showing classic type leakage on fluorescein angiography were included in the classic type leakage group (N = 40, 26.
View Article and Find Full Text PDFWhat is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis.
Liver Int
November 2024
Department of Health Promotion, Section of Gastroenterology and Hepatology, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
Background And Aims: Patients with overt or occult hepatitis B virus (HBV) infection receiving immunosuppressive treatments have a wide risk of HBV reactivation (HBVr). We performed meta-analysis with decision curve analyses (DCA) to estimate the risk of HBVr in HBsAg-negative anti-HBc-positive patients naïve to nucleos(t)ide analogues (NAs) receiving immunosuppressive treatments.
Approach And Results: Studies were identified through literature search until October 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!